AGN - What's Behind Allergan's Humdrum Q3 Results
Some pharmaceutical stocks might be struggling somewhat in 2019, but not Allergan (NYSE: AGN). Its shares are up more than 30% so far this year, with a big boost coming from AbbVie's decision to acquire Allergan.
Allergan announced its third-quarter results before the market opened on Tuesday. While those results didn't weigh heavily on the stock, they didn't generate tremendous enthusiasm, either. Here are the highlights from Allergan's Q3 update.
Image source: Getty Images.